Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer

Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer is a phase 2, interventional study registered as NCT07490119 by Fudan University, with a registry enrolment figure of 31 participants, started 2026-06-01 and due to reach its primary completion in 2028-06-01. Interventions recorded: Becotatug Vedotin; Cetuximab. Conditions listed: RAS Wild Type mCRC. Primary outcome: ORR. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed metastatic RAS wild-type colorectal cancer". No results are recorded here; the registry entry is the source.